Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like E*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000076	Eisai Inc.	04/17/2025	62856041030	DAYVIGO (lemborexant) 10mg Oral Tablet 30 count	01/23/2025	15.00	352.50	10/21/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Dayvigo (lemborexant) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on October 21, 2035.
Rx0000076	Eisai Inc.	04/17/2025	62856040530	DAYVIGO (lemborexant) 5mg Oral Tablet 30 count	01/23/2025	15.00	352.50	10/21/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Dayvigo (lemborexant) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on October 21, 2035.
Rx0000076	Eisai Inc.	04/17/2025	62856071405	Lenvatinib Mesylate 10 & 4 MG Capsule Therapy Pack 10 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071805	Lenvatinib Mesylate 10 MG & 2 x 4 MG Capsule Therapy Pack 15 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071005	Lenvatinib Mesylate 10 MG Capsule Therapy Pack 5 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856072405	Lenvatinib Mesylate 2 x 10 MG & 4 MG Capsule Therapy Pack 15 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856072005	Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 10 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856070805	Lenvatinib Mesylate 2 x 4 MG Capsule Therapy Pack 10 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071205	Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 15 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071230	Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 90 EA UU	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856070430	Lenvatinib Mesylate 4 MG Capsule Therapy Pack 30 EA UU	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856070405	Lenvatinib Mesylate 4 MG Capsule Therapy Pack 5 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856070830	LENVIMA (lenvatinib mesylate) 8 mg/day (4 mg x 2) 60 count	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071030	LENVIMA (lenvatinib mesylate)10 mg/day (10 mg x 1) 30 count	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071430	LENVIMA (lenvatinib mesylate)14 mg/day (10 mg x 1 and 4 mg x 1) 60 count	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071830	LENVIMA (lenvatinib) 18 mg/day (10 mg x 1 and 4 mg x 2) 30 day supply	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856072030	LENVIMA (lenvatinib) 20 mg/day (10 mg x 2) 30 day supply	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856072430	LENVIMA (lenvatinib) 24 mg/day (10 mg x 2 and 4 mg x 1) 30 day supply	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000114	Eli Lilly and Company	04/24/2025	00002481554	Verzenio Package Size: 14 Strength: 100 mg Dosage Form: TABLET	01/01/2025	231.09	4082.52	09/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Lilly did not acquire the product in the previous 5 years. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available.
Rx0000114	Eli Lilly and Company	04/24/2025	00002533754	Verzenio Package Size: 14 Strength: 150 mg Dosage Form: TABLET	01/01/2025	231.09	4082.52	09/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Lilly did not acquire the product in the previous 5 years. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available.
Rx0000114	Eli Lilly and Company	04/24/2025	00002621654	Verzenio Package Size: 14 Strength: 200 mg Dosage Form: TABLET	01/01/2025	231.09	4082.52	09/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Lilly did not acquire the product in the previous 5 years. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available.
Rx0000114	Eli Lilly and Company	04/24/2025	00002448354	Verzenio Package Size: 14 Strength: 50 mg Dosage Form: TABLET	01/01/2025	231.09	4082.52	09/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Lilly did not acquire the product in the previous 5 years. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available.
Rx0000079	EMD Serono, Inc.	04/24/2025	44087122501	Cetrotide 0.25 mg Injection 1 Vial, 1 Pre-filled Syringe Sterile Water, & 2 Needles	01/29/2025	15.05	316.12	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400006	Mavenclad 10 mg Tablet 1 x 2 and 4 x 1 Blister packs (6 count)	01/29/2025	2403.78	64839.06	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400007	Mavenclad 10 mg Tablet 2 x 2 and 3 x 1 Blister packs (7 count)	01/29/2025	2804.41	75645.57	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400008	Mavenclad 10 mg Tablet 3 x 2 and 2 x 1 Blister packs (8 count)	01/29/2025	3205.04	86452.08	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400004	Mavenclad 10 mg Tablet 4 x 1 Blister pack (4 count)	01/29/2025	1602.52	43226.04	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400009	Mavenclad 10 mg Tablet 4 x 2 and 1 x 1 Blister packs (9 count)	01/29/2025	3605.67	97258.59	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400005	Mavenclad 10 mg Tablet 5 x 1 Blister pack (5 count)	01/29/2025	2003.15	54032.55	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400000	Mavenclad 10 mg Tablet 5 x 2 Blister pack (10 count)	01/29/2025	4006.30	108065.10	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087115001	Ovidrel 250 ug/0.5 mL Injection Single Dose Pre-filled Syringe	01/29/2025	17.57	251.84	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087002203	Rebif 22 mcg/0.5 mL Injection 12 Single Dose Pre-filled Syringe	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087004403	Rebif 44 mcg/0.5 mL Injection 12 Single Dose Pre-filled Syringe	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087882201	Rebif 6 Single Dose Pre-filled Syringe 8.8 mcg/0.2 mL and 6 Single Dose Pre-filled Syringe 22 mcg/0.5 mL	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087332201	Rebif Rebidose 22 mcg/0.5 mL Injection 12 Single-Use Autoinjectors	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087334401	Rebif Rebidose 44 mcg/0.5 mL Injection 12 Single-Use Autoinjectors	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087018801	Rebif Rebidose 6 Single Dose 8.8 mcg/0.2 mL Pre-filled Autoinjectors & 6 Single Dose 22 mcg/ 0.5 mL Pre-filled Autoinjectors	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087500003	Tepmetko 225 mg Tablet 3 x 10 Blister pack (30 count)	01/09/2025	671.70	12883.20	03/19/2030	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087500006	Tepmetko 225 mg Tablet 6 x 10 Blister pack (60 count)	01/09/2025	1343.40	25766.40	03/19/2030	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000584	Endo USA, Inc.	04/30/2025	42023010501	BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL	02/24/2025	14.55	111.53	None	Single Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	92.36	85.92	1990	38.58	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244001002	Edex®, Alprostadil For Inj Kit 10 MCG, 2	01/01/2025	10.23	180.75	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	170.52	160.87	1998	78.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244001006	Edex®, Alprostadil For Inj Kit 10 MCG, 6	01/01/2025	30.70	542.32	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	511.62	482.66	1998	234.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244002002	Edex®, Alprostadil For Inj Kit 20 MCG, 2	01/01/2025	13.22	233.51	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	220.29	207.82	1998	100.75	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244002006	Edex®, Alprostadil For Inj Kit 20 MCG, 6	01/01/2025	39.65	700.49	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	660.84	623.43	1998	302.25	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244004002	Edex®, Alprostadil For Inj Kit 40 MCG, 2	01/01/2025	18.05	318.87	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	300.82	283.79	1998	137.60	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244004006	Edex®, Alprostadil For Inj Kit 40 MCG, 6	01/01/2025	54.15	956.57	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	902.42	851.34	1998	412.75	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481002509	FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9	01/01/2025	127.03	1410.21	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	1283.18	1167.59	2002	135.30	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481062970	PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100	01/01/2025	371.73	4126.53	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	3754.80	3416.56	2001	131.65	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481062770	PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100	01/01/2025	188.01	2087.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	1899.09	1728.02	1999	44.45	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481062370	PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100	01/01/2025	263.14	2921.07	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	2657.93	2418.50	1999	72.35	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481062870	PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100	01/01/2025	284.28	3155.82	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	2871.54	2612.87	2001	100.70	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244010010	THEO-24®, Theophylline Cap ER 24HR 100 MG, 100	01/01/2025	34.85	386.91	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	352.06	320.35	2008	136.73	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244020010	THEO-24®, Theophylline Cap ER 24HR 200 MG, 100	01/01/2025	51.80	575.03	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	523.23	476.10	2008	203.21	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244030010	THEO-24®, Theophylline Cap ER 24HR 300 MG, 100	01/01/2025	63.67	706.76	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	643.09	585.16	2008	249.75	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244040010	THEO-24®, Theophylline Cap ER 24HR 400 MG, 100	01/01/2025	89.59	994.51	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	904.92	823.40	2008	351.43	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	42023011925	TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl	02/24/2025	197.69	1515.63	None	Single Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	1255.18	1167.61	2006	164.78	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	71863010950	Alkindi Sprinkle (hydrocortisone) Oral Granules 0.5 MG, 50 Capsules, Bottle	01/10/2025	43.51	483.00	05/12/2034	Single Source Drug	None	None	None	1	Inflation and the rising costs of its development efforts, operations and support has impacted Eton’s business in recent years. The extended PBM processes to approve coverage and their unwillingness to approve prescribed drugs that are needed by patients also increases Eton’s cost of doing business.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	71863011050	Alkindi Sprinkle (hydrocortisone) Oral Granules 1 MG, 50 Capsules, Bottle	01/10/2025	87.02	966.00	05/12/2034	Single Source Drug	None	None	None	1	Inflation and the rising costs of its development efforts, operations and support has impacted Eton’s business in recent years. The extended PBM processes to approve coverage and their unwillingness to approve prescribed drugs that are needed by patients also increases Eton’s cost of doing business.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	71863011150	Alkindi Sprinkle (hydrocortisone) Oral Granules 2 MG, 50 Capsules, Bottle	01/10/2025	174.04	1932.00	05/12/2034	Single Source Drug	None	None	None	1	Inflation and the rising costs of its development efforts, operations and support has impacted Eton’s business in recent years. The extended PBM processes to approve coverage and their unwillingness to approve prescribed drugs that are needed by patients also increases Eton’s cost of doing business.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	71863011250	Alkindi Sprinkle (hydrocortisone) Oral Granules 5 MG, 50 Capsules, Bottle	01/10/2025	435.09	4829.89	05/12/2034	Single Source Drug	None	None	None	1	Inflation and the rising costs of its development efforts, operations and support has impacted Eton’s business in recent years. The extended PBM processes to approve coverage and their unwillingness to approve prescribed drugs that are needed by patients also increases Eton’s cost of doing business.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	15054104005	Increlex 40 mg/4 mL Subcutaneous Solution 4 mL MDV 1 carton	02/18/2025	8823.00	14705.00	None	Single Source Drug	None	None	None	1	Eton is investing significant additional resources into the product which we believe will be beneficial to patients. In particular, we are investing resources in an improved distribution model which we anticipate will make the product more accessible  for patients. Furthermore, we are integrating the product into a single hub system for improved and more streamlined access. Finally we are devoting additional resources to the sales and marketing of the product which we believe will improve both awareness and accessibility.	None	No change or improvement.	None	12/19/2024	Ipsen Biopharmaceuticals, Inc.	35000000	None	None	5882.00	5882.00	2006	450.00	None	None